Welcome to the Asan Preclinical Evaluation Center for Cancer TherapeutiX (APEX)
Asan Medical Center, the top-ranked hospital in Korea, has been at the forefront of enhancing cancer drug development through a series of national projects, including the Center for Development and Commercialization of Anti-cancer Therapeutics (CDCAT, 2010-2015), the T2B (Technology to Business) Infrastructure Center for Advancing Cancer Therapeutics (CACT, 2015-2020), and the Asan Preclinical Evaluation center for cancer therapeuticX (APEX, 2020-2023).
Since August 2023, with the support of the Ministry of Health and Welfare, APEX has been offering specialized preclinical research services to accelerate the development of cancer therapeutics.
Our expertise covers a comprehensive range of in vivo non-GLP and GLP safety assessments in both rodent and non-rodent models, providing thorough evaluations of pharmaceuticals and biologics.
Our dedicated scientific and professional teams design customized research programs and conduct tailored preclinical studies to ensure the success of your drug development pipeline.
APEX is committed to enhancing the clinical and commercial success rates of new drug development. We strive to fulfill the national mission of strengthening the international competitiveness of the healthcare technology (HT) and biotechnology (BT) industries.